Loading clinical trials...
Loading clinical trials...
The objective of the International Rare Brain Tumor Registry (IRBTR) is to better understand rare brain tumors through the collection of biospecimens and matched clinical data of children, adolescents, and young adult patients diagnosed with rare brain tumors.
The International Rare Brain Tumor Registry (IRBTR) is a prospective observational study that will collect tumor samples and matched clinical and radiological data to better understand the outcomes of patients with rare brain tumors in particular: CNS sarcoma, BCOR, MN-1 altered tumors, PLAG/L1, and other rare or unclassified rare brain tumors. Data collected include demographics, disease characteristics, treatment information, radiological imaging, and biospecimen collection if available ( tumor tissues Patients will be followed longitudinally to obtain outcome data. Data collection will continue for approximately 10 years.
Age
0 - 45 years
Sex
ALL
Healthy Volunteers
No
Nathan Robison
Los Angeles, California, United States
Marie Jaeger-Krause
San Francisco, California, United States
Children's National Hospital
Washington D.C., District of Columbia, United States
Scott Raskin
Cincinnati, Ohio, United States
Start Date
January 1, 2023
Primary Completion Date
December 1, 2033
Completion Date
December 1, 2033
Last Updated
September 8, 2025
5,800
ESTIMATED participants
Lead Sponsor
Children's National Research Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions